Abstract Sulbactam/durlobactam (XACDURO®), is a co-packaged antibacterial product that
has been developed by Entasis Therapeutics Inc. for the treatment of infections caused by …

Sulbactam-durlobactam is a β-lactam/β-lactamase inhibitor combination currently in
development for the treatment of infections caused by Acinetobacter, including multidrug …

Acinetobacter baumannii-calcoaceticus complex (ABC) organisms cause severe infections
that are difficult to treat due to preexisting antibiotic resistance. Sulbactam-durlobactam …

Sulbactam-durlobactam is a pathogen-targeted β-lactam/β-lactamase inhibitor combination
in late-stage development for the treatment of Acinetobacter infections, including those …

Multi-drug resistant (MDR) Acinetobacter baumannii is emerging as a pathogen of
increasing prevalence and concern. Infections associated with this Gram-negative pathogen …

Sulbactam-durlobactam is a β-lactam-β-lactamase inhibitor combination designed to treat
serious Acinetobacter baumannii-calcoaceticus complex (ABC) infections, including …

Infections caused by Acinetobacter baumannii are increasingly multidrug resistant and
associated with high rates of morbidity and mortality. Sulbactam is a β-lactamase inhibitor …

Acinetobacter baumannii-calcoaceticus complex (ABC) causes severe infections that are
difficult to treat due to pre-existing antibiotic resistance. Sulbactam-durlobactam (SUL-DUR) …

Background Acinetobacter baumannii is a leading cause of healthcare-associated infections
worldwide, due to both its persistence in the hospital setting and ability to acquire high levels …

An increasing number of untreatable infections are recorded every year. Many studies have
focused their efforts on developing new β-lactamase inhibitors to treat multi-drug resistant …